The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction
Phase 4
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Registration Number
- NCT00882466
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
The purpose of this study is to investigate the effect of intravenous human recombinant erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in patients with acute myocardial infarction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
- Acute myocardial infarction <12hr
- Age >18yrs
- First myocardial infarction
- culprit lesion : proximal to mid left anterior descending artery
- Baseline coronary flow : TIMI Grade 0~1
Exclusion Criteria
- Patients with previous myocardial infarction
- History of thrombotic complication
- History of cerebral infarction
- Uncontrolled hypertension
- Increased hemoglobin level >17g/dL
- Patients with mechanical valve
- Cardiogenic shock
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description EPO human recombinant erythropoietin -
- Primary Outcome Measures
Name Time Method Creatinine kinase (CK), creatinine kinase-MB (CK-MB) 4hr, 8hr, 12hr, 24hr, 48hr, 72hr
- Secondary Outcome Measures
Name Time Method Infarct size assessed by cardiac MRI day 4
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does human recombinant erythropoietin target to reduce reperfusion injury in acute myocardial infarction?
How does erythropoietin compare to standard-of-care treatments in mitigating myocardial reperfusion injury?
Which biomarkers are associated with response to erythropoietin therapy in acute myocardial infarction patients?
What are the potential adverse events of administering erythropoietin during reperfusion in AMI patients?
Are there combination therapies involving erythropoietin and anti-apoptotic agents for acute myocardial infarction?
Trial Locations
- Locations (1)
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of
Seoul National University Bundang Hospital🇰🇷Seongnam, Korea, Republic of